Form 4: Phibro CEO Sells Shares, Converts Stock

Phibro Animal Health CEO Jack Bendheim, through BFI Co., LLC, sold 7,022 Class A shares and converted 30,000 Class B shares to Class A.

Summary

• Jack Bendheim, President and CEO, Director, and 10% Owner of Phibro Animal Health Corp (PAHC), through BFI Co., LLC, reported transactions involving Class A and Class B Common Stock.
• On September 18, 2025, BFI Co., LLC sold 7,022 shares of Class A Common Stock at a weighted average price of $40.2637 per share, with prices ranging from $40.00 to $40.51.
• This sale was executed under a Rule 10b5-1 trading plan adopted by BFI Co., LLC on May 30, 2025.
• On September 19, 2025, BFI Co., LLC converted 30,000 shares of Class B Common Stock into 30,000 shares of Class A Common Stock. Class B Common Stock is convertible on a one-for-one basis at the holder's election and has no expiration date.
• Following these transactions, BFI Co., LLC indirectly beneficially owns 61,338 shares of Class A Common Stock and 20,136,034 shares of Class B Common Stock.
• Jack Bendheim directly holds 16,840 shares of Class A Common Stock.
• Mr. Bendheim exercises voting and dispositive power over BFI Co., LLC and disclaims beneficial ownership of BFI's securities except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: The filing reports routine, pre-planned insider transactions (a sale and a conversion) which are generally considered neutral in sentiment unless they are unusually large or unexpected. The 10b5-1 plan adds transparency.

Positives

• The sale of Class A Common Stock was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a structured and transparent approach to insider transactions.
• The conversion of Class B to Class A Common Stock can enhance the liquidity and tradability of the converted shares.

Negatives

• The sale of 7,022 Class A Common Stock shares by an insider, even if planned, could be perceived as a slight negative signal regarding future prospects or valuation.

Risks

• No specific new risks are introduced by this Form 4 filing beyond the general market perception of insider selling.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing reports routine insider transactions and does not provide specific information relating to broader industry trends or competitors within the animal health sector.

Corporate Governance

Related Party Transactions

• Transactions by BFI Co., LLC are considered related-party transactions as Jack Bendheim, President and CEO, Director, and 10% Owner, exercises voting and dispositive power over BFI Co., LLC.

Stakeholder Impact

• Shareholders: Minor impact from a planned insider sale and conversion. The conversion of Class B to Class A shares may slightly increase the liquidity of Class A shares available in the market.
• Management: Jack Bendheim continues in his roles, and the transactions are part of a pre-arranged plan, indicating personal financial management rather than a change in company strategy.

Key Dates

Recommendation

The filing details a pre-planned insider stock sale and a conversion of Class B to Class A shares. While insider selling can sometimes be a negative signal, the execution under a Rule 10b5-1 plan suggests a structured personal financial management decision rather than a reaction to new, adverse company-specific information. The conversion to Class A shares could be seen as a move to increase liquidity. Given the planned nature and the relatively modest size of the sale compared to total holdings, this filing alone does not provide a strong catalyst for a 'buy' or 'sell' recommendation, thus a 'hold' is appropriate for seasoned investors awaiting further operational or financial updates.

Keywords

PHIBRO ANIMAL HEALTH, PAHC, insider trading, Form 4, stock sale, stock conversion, Jack Bendheim, BFI Co., LLC, Rule 10b5-1